Patients who regularly took the COX-2 selective NSAID celecoxib (Pfizer's Celebrex) over three years were less likely to develop colorectal polyps, but after two years off treatment, the celecoxib group was more likely than the placebo group to have new adenomas, according to a study in The American Journal of Gastroenterology. The report by researchers at Israel's Tel Aviv University -- supported by Pfizer -- looked at data from 1,561 patients with a history of colon adenomas. More than half took celecoxib for about three years before concerns over cardiovascular risks ended the project. Read the abstract.
Published in Brief: